Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
AssigneeCornell Research Foundation, Inc.
InventorsSteven S. Gross, Caroline L. Jones
Life of this patent
Estimating the term…
Abstract
A patient with a disorder involving endothelial dysfunction associated with deficient nitric oxide bioactivity, e.g., coronary artery disease, atherosclerosis, hypertension, diabetes or neurodegenerative condition stemming from ischemia and/or inflammation, is treated by administering nitric oxide bioactivity increasing hydroxyguanidine.
Claims18
A method for treating a disorder which is endothelial dysfunction associated with deficient nitric oxide bioactivity caused by oxidative stress in a patient in need thereof, comprising administering to the patient an endothelial dysfunction reversing or diminishing effective amount of an agent which is selected from the group consisting of nitric oxide bioactivity increasing hydroxyguanidines and pharmaceutically acceptable salts thereof.
A method for treating Type-1 diabetes involving endothelial dysfunction associated with deficient nitric oxide bioactivity caused by oxidative stress in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nitric oxide bioactivity increasing compound having the formula:
- wherein R1, R2, R3 and R4 permit transport in cells and are the same or different and can be independently selected from the group consisting of hydrogen, amino, imino, alkyl, substituted alkyl, phenyl, substituted phenyl, cycloalkyl, benzyl, acyl, pyridyl, piperidyl, piperazyl, amino acid, lipid or carbohydrate and where R3 and R4 can optionally join to form a ring.
A method for treating Type-2 diabetes involving endothelial dysfunction associated with deficient nitric oxide bioactivity caused by oxidative stress in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nitric oxide bioactivity increasing compound having the formula:
- wherein R1, R2, R3 and R4 permit transport into cells and are the same or different and can be independently selected from the group consisting of hydrogen, amino, imino, alkyl, substituted alkyl, phenyl, substituted phenyl, cycloalkyl, benzyl, acyl, pyridyl, piperidyl, piperazyl, amino acid, lipid or carbohydrate and where R3 and R4 can optionally join to form a ring.
Dependencies are inferred from the claim text.